Gastrointestinal Bleeding Treatment Market Benefits, Technology Advancement and Future Scope Till 2026
Gastrointestinal bleeding, also known as gastrointestinal hemorrhage, is all forms of bleeding in the gastrointestinal tract – from the mouth to the rectum. The symptoms of gastrointestinal bleeding depend on the acuteness and the source of the blood loss. Mild, chronic gastrointestinal blood loss is not likely to indicate any active bleeding; however, it can still result in an iron-deficiency anemia. Many such patients never notice any blood loss; however, it occurs in small amounts with the bowel movement and hence, it is not noticeable. Gastrointestinal bleeding is an important concern in patients treated with direct oral anticoagulants (DOACs). Gastrointestinal bleeding is a common complication of hepatocellular carcinoma (HCC). Common etiologies include peptic ulcer disease, variceal bleeding due to portal hypertension from underlying cirrhosis and/or tumor, invasion of portal vein causing thrombosis, and portal hypertensive gastropathy. Acute or overt gastrointestinal bleeding is visible in the form of hematemesis, melena, or hematochezia. Chronic or occult gastrointestinal bleeding is not apparent to the patient and usually presents as positive fecal occult blood or iron-deficiency anemia.
For more details, request a sample report @ https://www.marketresearchreports.biz/sample/sample/5990
Causes of gastrointestinal bleeding include gastric ulcers, artery or vein (arteriovenous) malformations, diverticulosis, cancer, or inflammatory bowel disease. Geriatric patients are at a higher risk of death due to severe GI bleeding. Increasing prevalence of upper gastrointestinal bleedings, gastric ulcers, and increasing awareness about gastrointestinal diseases are some factors that are likely to drive the gastrointestinal bleeding treatment market during the forecast period. GI bleeding is a common problem medical practitioners encounter in the emergency department and in the primary care setting. According to the National Center for Biotechnology Information, annual hospital admissions for GI bleeding in the U.S. and the U.K. have been estimated to be up to 150 patients per 100000 population with a 5% to 10% mortality rate. While GI bleeding can be potentially life-threatening, it has been witnessed that in many cases, it can be safely managed on an outpatient basis.
The global gastrointestinal bleeding treatment market can be segmented based on product type, gastrointestinal tract division, end-user, and region. Based on product type, the gastrointestinal bleeding treatment market can be segregated into hemostasis devices, closure devices, and others. In terms of gastrointestinal tract division, the gastrointestinal bleeding treatment market can be classified into upper gastrointestinal and lower gastrointestinal. Based on end-user, the gastrointestinal bleeding treatment market can be split into hospitals, clinics, ambulatory surgical centers, and others.
In terms of region, the gastrointestinal bleeding treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for a larger share of the market, and the trend is expected to continue during the forecast period. Expansion of the market is attributed to the increasing incidence of gastrointestinal bleeding in the U.S. and approval of new products. Acute gastrointestinal bleeding is a major cause of hospital admissions in the U.S., which is estimated at 300,000 patients annually. In May 2018, the U.S. Food and Drug Administration permitted marketing of Cook Medical’s Hemospray, a new device used to help control certain types of bleeding in the gastrointestinal (GI) tract. Europe was also a significant market for gastrointestinal bleeding treatment market due to the increasing demand for technological advancements. Asia Pacific gastrointestinal bleeding treatment market is expected to expand at a comparatively higher CAGR during the forecast period. The higher growth rate is attributed to the increasing spending on healthcare, rising demand for and awareness about advanced products, and increasing prevalence of upper gastrointestinal bleeding (UGIB).
Read Complete Table of Content of the Report at: https://www.marketresearchreports.biz/sample/toc/5990
Key players operating in the global gastrointestinal bleeding treatment market include Cook Medical, Boston Scientific Corporation, and Olympus Corporation.
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
- Tailwinds and headwinds molding the market’s trajectory
- Market segments based on products, technology, and applications
- Prospects of each segment
- Overall current and possible future size of the market
- Growth pace of the market
- Competitive landscape and key players’ strategies
The main aim of the report is to:
- Enable key stakeholder’s in the market bet right on it
- Understand the opportunities and pitfalls awaiting them
- Assess the overall growth scope in the near term
- Strategize effectively with respect to production and distribution
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.